These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17145348)

  • 1. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?
    Prowell TM; Armstrong DK
    Semin Oncol; 2006 Dec; 33(6):681-7. PubMed ID: 17145348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
    Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
    Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implication of HER-2/neu overexpression for the efficacy of oral fluoropyrimidine-based adjuvant chemotherapy in the patients with estrogen receptor negative breast cancer after surgery.
    Nio Y; Itakura M; Omori H; Koike M; Hashimoto K; Yano S; Toga T; Higami T
    Anticancer Res; 2003; 23(1B):745-53. PubMed ID: 12680178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.
    Ciocca DR; Gago FE; Fanelli MA; Calderwood SK
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):32-40. PubMed ID: 17049840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
    Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
    Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
    De Laurentiis M; Arpino G; Massarelli E; Ruggiero A; Carlomagno C; Ciardiello F; Tortora G; D'Agostino D; Caputo F; Cancello G; Montagna E; Malorni L; Zinno L; Lauria R; Bianco AR; De Placido S
    Clin Cancer Res; 2005 Jul; 11(13):4741-8. PubMed ID: 16000569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
    Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
    J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple positive breast cancer: a distinct subtype?
    Vici P; Pizzuti L; Natoli C; Gamucci T; Di Lauro L; Barba M; Sergi D; Botti C; Michelotti A; Moscetti L; Mariani L; Izzo F; D'Onofrio L; Sperduti I; Conti F; Rossi V; Cassano A; Maugeri-Saccà M; Mottolese M; Marchetti P
    Cancer Treat Rev; 2015 Feb; 41(2):69-76. PubMed ID: 25554445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of response to systemic therapy in breast cancer.
    Ring AE; Ellis PA
    Forum (Genova); 2002; 12(1):19-32. PubMed ID: 12634908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts.
    Stark A; Lu M; Mackowiak P; Linden M
    Breast J; 2005; 11(3):183-7. PubMed ID: 15871703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.